Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Coronaviruses
  4. Fast Track Articles
  5. Fast Track Article
image of Revisiting the COVID-19 Pandemic: A Comparative Analysis between Traditional and Synthetic Modes of Treatment with the Aid of In-silico Methods

Abstract

Introduction/Background

The COVID-19 pandemic has severely disrupted global health systems, highlighting the urgent need for effective treatment strategies. This article aims to provide an assessment of the pandemic's current status and examines the effectiveness of traditional treatments against innovative synthetic approaches.

Materials and Methods

The article explores synthetic strategies involving repurposed antiviral drugs, supportive care, and vaccinations. It emphasizes the role of computational modeling and artificial intelligence in engineering molecules with potent antiviral properties. methods were utilized to accelerate chemical library screenings, predict efficacy, and assess interactions between viral proteins and potential treatments.

Results

Studies employing molecular docking analysis have evaluated the efficacy of approved antiviral drugs and natural compounds. Notably, Azithromycin was found to have a potential inhibitory effect with a binding energy of -9.69, while natural compounds like Camphor and Curcumin displayed binding energies of -5.18 and -6.16, respectively.

Discussion

Synthetic treatments showed effectiveness in inhibiting viral proteins and facilitating rapid development, while natural products were more effective in preventing virus entry.

Conclusion

Based on in-silico docking studies, it can be concluded that natural products have more therapeutic effects than synthetic drugs.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/covid/10.2174/0126667975310159241008050626
2024-10-16
2024-11-22

  • From This Site

    /content/journals/covid/10.2174/0126667975310159241008050626
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Muralidar S. Ambi S.V. Sekaran S. Krishnan U.M. The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie 2020 179 85 100 10.1016/j.biochi.2020.09.018 32971147
    [Google Scholar]
  2. Atzrodt C.L. Maknojia I. McCarthy R.D.P. Oldfield T.M. Po J. Ta K.T.L. Stepp H.E. Clements T.P. A Guide to COVID‐19: A global pandemic caused by the novel coronavirus SARS‐CoV‐2. FEBS J. 2020 287 17 3633 3650 10.1111/febs.15375 32446285
    [Google Scholar]
  3. Nazi Nejat Ali Jadidi Hezave A.K. Pour S.M.A. Prevention and treatment of COVID-19 Using traditional and folk medicine: A content analysis study. Ethiop. J. Health Sci. 2021 31 6 1089 1098 10.4314/ejhs.v31i6.3 35392333
    [Google Scholar]
  4. Aghamirza Moghim Aliabadi H. Eivazzadeh-Keihan R. Beig Parikhani A. Fattahi Mehraban S. Maleki A. Fereshteh S. Bazaz M. Zolriasatein A. Bozorgnia B. Rahmati S. Saberi F. Yousefi Najafabadi Z. Damough S. Mohseni S. Salehzadeh H. Khakyzadeh V. Madanchi H. Kardar G.A. Zarrintaj P. Saeb M.R. Mozafari M. COVID‐19: A systematic review and update on prevention, diagnosis, and treatment. MedComm 2022 3 1 e115 10.1002/mco2.115 35281790
    [Google Scholar]
  5. Shaker B. Ahmad S. Lee J. Jung C. Na D. In silico methods and tools for drug discovery. Comput. Biol. Med. 2021 137 104851 10.1016/j.compbiomed.2021.104851 34520990
    [Google Scholar]
  6. Fokunang C.N. Ndikum V. Tabi O.Y. Jiofack R.B. Ngameni B. Guedje N.M. Tembe-Fokunang E.A. Tomkins P. Barkwan S. Kechia F. Asongalem E. Ngoupayou J. Torimiro N.J. Gonsu K.H. Sielinou V. Ngadjui B.T. Angwafor I.I.I. III Nkongmeneck A. Abena O.M. Ngogang J. Asonganyi T. Colizzi V. Lohoue J. Kamsu-Kom Traditional medicine: Past, present and future research and development prospects and integration in the national health system of Cameroon. Afr. J. Tradit. Complement. Altern. Med. 2011 8 3 284 295 10.4314/ajtcam.v8i3.65276 22468007
    [Google Scholar]
  7. Lai Y. Chu X. Di L. Gao W. Guo Y. Liu X. Lu C. Mao J. Shen H. Tang H. Xia C.Q. Zhang L. Ding X. Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development. Acta Pharm. Sin. B 2022 12 6 2751 2777 10.1016/j.apsb.2022.03.009 35755285
    [Google Scholar]
  8. Sliwoski G. Kothiwale S. Meiler J. Lowe E.W. Jr Computational methods in drug discovery. Pharmacol. Rev. 2014 66 1 334 395 10.1124/pr.112.007336 24381236
    [Google Scholar]
  9. Yildirim F.S. Sayan M. Sanlidag T. Uzun B. Ozsahin D.U. Ozsahin I. Comparative evaluation of the treatment of COVID-19 with multicriteria decision-making techniques. J. Healthc. Eng. 2021 2021 1 11 10.1155/2021/8864522 33552457
    [Google Scholar]
  10. Lisco G. Giagulli V.A. De Pergola G. De Tullio A. Guastamacchia E. Triggiani V. Covid-19 in Man: A very dangerous affair. Endocr. Metab. Immune Disord. Drug Targets 2021 21 9 1544 1554 10.2174/22123873MTEyAOTQiz 33388025
    [Google Scholar]
  11. White A. Men and COVID-19: The aftermath. Postgrad. Med. 2020 132 sup4 18 27 10.1080/00325481.2020.1823760 32921214
    [Google Scholar]
  12. Lipsky M.S. Hung M. Men and COVID-19: A pathophysiologic review. Am. J. Men Health 2020 14 5 10.1177/1557988320954021 32936693
    [Google Scholar]
  13. Pijls B.G. Jolani S. Atherley A. Derckx R.T. Dijkstra J.I.R. Franssen G.H.L. Hendriks S. Richters A. Venemans-Jellema A. Zalpuri S. Zeegers M.P. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: A meta-analysis of 59 studies. BMJ Open 2021 11 1 e044640 10.1136/bmjopen‑2020‑044640 33431495
    [Google Scholar]
  14. Sansone A. Mollaioli D. Ciocca G. Limoncin E. Colonnello E. Vena W. Jannini E.A. Addressing male sexual and reproductive health in the wake of COVID-19 outbreak. J. Endocrinol. Invest. 2021 44 2 223 231 10.1007/s40618‑020‑01350‑1 32661947
    [Google Scholar]
  15. Peters M.D.J. Godfrey C.M. Khalil H. McInerney P. Parker D. Soares C.B. Guidance for conducting systematic scoping reviews. Int. J. Evid.-Based Healthc. 2015 13 3 141 146 10.1097/XEB.0000000000000050 26134548
    [Google Scholar]
  16. Munn Z. Peters M.D.J. Stern C. Tufanaru C. McArthur A. Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med. Res. Methodol. 2018 18 1 143 10.1186/s12874‑018‑0611‑x 30453902
    [Google Scholar]
  17. Pham M.T. Rajić A. Greig J.D. Sargeant J.M. Papadopoulos A. McEwen S.A. A scoping review of scoping reviews: Advancing the approach and enhancing the consistency. Res. Synth. Methods 2014 5 4 371 385 10.1002/jrsm.1123 26052958
    [Google Scholar]
  18. Demeke C.A. Woldeyohanins A.E. Kifle Z.D. Herbal medicine use for the management of COVID-19: A review article. Metab. Open 2021 12 100141 10.1016/j.metop.2021.100141 34693242
    [Google Scholar]
  19. Khan T.A. Camphor and respiratory epidemics: The promise of a divine remedy. 2020 Available from: https://www.alhakam.org/camphor-and-respiratory-epidemics-the-promise-of-a-divine-remedy/
  20. Babaei F. Nassiri-Asl M. Hosseinzadeh H. Curcumin (a constituent of turmeric): New treatment option against COVID‐19. Food Sci. Nutr. 2020 8 10 5215 5227 10.1002/fsn3.1858 33133525
    [Google Scholar]
  21. Khan T. Khan M.A. Mashwani Z.R. Ullah N. Nadhman A. Therapeutic potential of medicinal plants against COVID-19: The role of antiviral medicinal metabolites. Biocatal. Agric. Biotechnol. 2021 31 101890 10.1016/j.bcab.2020.101890 33520034
    [Google Scholar]
  22. Wu H. Ji C. Dai R. Hei P. Liang J. Wu X. Li Q. Yang J. Mao W. Guo Q. Traditional Chinese medicine treatment for COVID-19: An overview of systematic reviews and meta-analyses. J. Integr. Med. 2022 20 5 416 426 10.1016/j.joim.2022.06.006 35811240
    [Google Scholar]
  23. Wang Q. Zhu H. Li M. Liu Y. Lai H. Yang Q. Cao X. Ge L. Efficacy and safety of qingfei paidu decoction for treating COVID-19: A systematic review and meta-analysis. Front. Pharmacol. 2021 12 688857 10.3389/fphar.2021.688857 34456720
    [Google Scholar]
  24. Lu Y. Zhang M. Yang Q. Li W. Yang K. Hu W. Gao S. Jiang Q. Lin L. Cheng H. Sun F. Effectiveness and safety of Lianhua Qingwen capsules for COVID‐19: A propensity‐score matched cohort study. Evid. Based Complement. Alternat. Med. 2023 2023 1 6028554 10.1155/2023/6028554 36846053
    [Google Scholar]
  25. Li Y. Xiao P. Liu N. Zhang Z. Efficacy and Safety of Chinese Medicine Lianhua Qingwen for Treating COVID-19: An Updated meta-Analysis. Front. Pharmacol. 2022 13 888820 10.3389/fphar.2022.888820 35721166
    [Google Scholar]
  26. Panyod S. Ho C.T. Sheen L.Y. Dietary therapy and herbal medicine for COVID-19 prevention: A review and perspective. J. Tradit. Complement. Med. 2020 10 4 420 427 10.1016/j.jtcme.2020.05.004 32691006
    [Google Scholar]
  27. Hadni H. Fitri A. Benjelloun A.T. Benzakour M. Mcharfi M. Evaluation of flavonoids as potential inhibitors of the SARS-CoV-2 main protease and spike RBD: Molecular docking, ADMET evaluation and molecular dynamics simulations. J. Indian Chem. Soc. 2022 99 10 100697 10.1016/j.jics.2022.100697
    [Google Scholar]
  28. Wang Z. Song X. Xu W. Lei S. Zhang H. Yang L. Stand up to stand out: Natural dietary polyphenols curcumin, resveratrol, and gossypol as potential therapeutic candidates against severe acute respiratory syndrome coronavirus 2 infection. Nutrients 2023 15 18 3885 10.3390/nu15183885 37764669
    [Google Scholar]
  29. Chao W.W. Lin B.F. Isolation and identification of bioactive compounds in Andrographis paniculata (Chuanxinlian). Chin. Med. 2010 5 1 17 10.1186/1749‑8546‑5‑17 20465823
    [Google Scholar]
  30. Bisht D. Rashid M. Arya R.K.K. Kumar D. Chaudhary S.K. Rana V.S. Sethiya N.K. Revisiting liquorice (Glycyrrhiza glabra L.) as anti-inflammatory, antivirals and immunomodulators: Potential pharmacological applications with mechanistic insight. Phytomed. Plus 2022 2 1 100206 10.1016/j.phyplu.2021.100206 35403088
    [Google Scholar]
  31. Zhao T. Li C. Wang S. Song X. Green Tea (Camellia sinensis): a review of its phytochemistry, pharmacology, and toxicology. Molecules 2022 27 12 3909 10.3390/molecules27123909 35745040
    [Google Scholar]
  32. Chien T.J. Liu C.Y. Chang Y.I. Fang C.J. Pai J.H. Wu Y.X. Chen S.W. Therapeutic effects of herbal-medicine combined therapy for COVID-19: A systematic review and meta-analysis of randomized controlled trials. Front. Pharmacol. 2022 13 950012 10.3389/fphar.2022.950012 36120361
    [Google Scholar]
  33. Lai C.C. Wang Y.H. Chen K.H. Chen C.H. Wang C.Y. The clinical efficacy and safety of anti-viral agents for non-hospitalized patients with COVID-19: A systematic review and network meta-analysis of randomized controlled trials. Viruses 2022 14 8 1706 10.3390/v14081706 36016328
    [Google Scholar]
  34. Sohail M.I. Siddiqui A. Erum N. Kamran M. Phytomedicine and the COVID-19 pandemic. In: Phytomedicine: A Treasure of Pharmacologically Active Products from Plants Academic Press 2021 693 708 10.1016/B978‑0‑12‑824109‑7.00005‑4
    [Google Scholar]
  35. Vellingiri B. Jayaramayya K. Iyer M. Narayanasamy A. Govindasamy V. Giridharan B. Ganesan S. Venugopal A. Venkatesan D. Ganesan H. Rajagopalan K. Rahman P.K.S.M. Cho S.G. Kumar N.S. Subramaniam M.D. COVID-19: A promising cure for the global panic. Sci. Total Environ. 2020 725 138277 10.1016/j.scitotenv.2020.138277 32278175
    [Google Scholar]
  36. Kumar A. Rai A. Khan M.S. Kumar A. Haque Z.U. Fazil M. Rabbani G. Role of herbal medicines in the management of patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. J. Tradit. Complement. Med. 2022 12 1 100 113 10.1016/j.jtcme.2022.01.002 35036347
    [Google Scholar]
  37. Vegivinti C.T.R. Evanson K.W. Lyons H. Akosman I. Barrett A. Hardy N. Kane B. Keesari P.R. Pulakurthi Y.S. Sheffels E. Balasubramanian P. Chibbar R. Chittajallu S. Cowie K. Karon J. Siegel L. Tarchand R. Zinn C. Gupta N. Kallmes K.M. Saravu K. Touchette J. Efficacy of antiviral therapies for COVID-19: A systematic review of randomized controlled trials. BMC Infect. Dis. 2022 22 1 107 10.1186/s12879‑022‑07068‑0 35100985
    [Google Scholar]
  38. Tasavon Gholamhoseini M. Yazdi-Feyzabadi V. Goudarzi R. Mehrolhassani M.H. Safety and Efficacy of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis. J. Pharm. Pharm. Sci. 2021 24 237 245 10.18433/jpps31870 34048669
    [Google Scholar]
  39. Akinosoglou K. Schinas G. Gogos C. Oral antiviral treatment for COVID-19: A comprehensive review on nirmatrelvir/ritonavir. Viruses 2022 14 11 2540 10.3390/v14112540 36423149
    [Google Scholar]
  40. Zeitlinger M. Koch B.C.P. Bruggemann R. De Cock P. Felton T. Hites M. Le J. Luque S. MacGowan A.P. Marriott D.J.E. Muller A.E. Nadrah K. Paterson D.L. Standing J.F. Telles J.P. Wölfl-Duchek M. Thy M. Roberts J.A. Pharmacokinetics/pharmacodynamics of antiviral agents used to treat sars-CoV-2 and their potential interaction with drugs and other supportive measures: A Comprehensive review by the pk/pd of anti-infectives study group of the European Society of Antimicrobial Agents. Clin. Pharmacokinet. 2020 59 10 1195 1216 10.1007/s40262‑020‑00924‑9 32725382
    [Google Scholar]
  41. Duan Y. Zhou H. Liu X. Iketani S. Lin M. Zhang X. Bian Q. Wang H. Sun H. Hong S.J. Culbertson B. Mohri H. Luck M.I. Zhu Y. Liu X. Lu Y. Yang X. Yang K. Sabo Y. Chavez A. Goff S.P. Rao Z. Ho D.D. Yang H. Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir. Nature 2023 622 7982 376 382 10.1038/s41586‑023‑06609‑0 37696289
    [Google Scholar]
  42. Frediansyah A. Tiwari R. Sharun K. Dhama K. Harapan H. Antivirals for COVID-19: A critical review. Clin. Epidemiol. Glob. Health 2021 9 90 98 10.1016/j.cegh.2020.07.006 33521390
    [Google Scholar]
  43. Mikulska M. Sepulcri C. Dentone C. Magne F. Balletto E. Baldi F. Labate L. Russo C. Mirabella M. Magnasco L. Di Grazia C. Ghiggi C. Raiola A.M. Giacobbe D.R. Vena A. Beltramini S. Bruzzone B. Lemoli R.M. Angelucci E. Bassetti M. Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients. Clin. Infect. Dis. 2023 77 2 280 286 10.1093/cid/ciad181 36976301
    [Google Scholar]
  44. Takahashi T. Luzum J.A. Nicol M.R. Jacobson P.A. Pharmacogenomics of COVID-19 therapies. NPJ Genom. Med. 2020 5 1 35 10.1038/s41525‑020‑00143‑y 32864162
    [Google Scholar]
  45. Smith L.E. D’Antoni D. Jain V. Pearce J.M. Weinman J. Rubin G.J. A systematic review of factors affecting intended and actual adherence with antiviral medication as treatment or prophylaxis in seasonal and pandemic flu. Influenza Other Respir. Viruses 2016 10 6 462 478 10.1111/irv.12406 27397480
    [Google Scholar]
  46. Dawoud D.M. Soliman K.Y. Cost-effectiveness of antiviral treatments for pandemics and outbreaks of respiratory illnesses, including covid-19: a systematic review of published economic evaluations. Value Health 2020 23 11 1409 1422 10.1016/j.jval.2020.07.002 33127010
    [Google Scholar]
  47. Rezaee H. Pourkarim F. Pourtaghi-Anvarian S. Entezari-Maleki T. Asvadi-Kermani T. Nouri-Vaskeh M. Drug‐drug interactions with candidate medications used for COVID‐19 treatment: An overview. Pharmacol. Res. Perspect. 2021 9 1 e00705 10.1002/prp2.705 33421347
    [Google Scholar]
  48. Chiotos K. Hayes M. Kimberlin D.W. Jones S.B. James S.H. Pinninti S.G. Yarbrough A. Abzug M.J. MacBrayne C.E. Soma V.L. Dulek D.E. Vora S.B. Waghmare A. Wolf J. Olivero R. Grapentine S. Wattier R.L. Bio L. Cross S.J. Dillman N.O. Downes K.J. Oliveira C.R. Timberlake K. Young J. Orscheln R.C. Tamma P.D. Schwenk H.T. Zachariah P. Aldrich M.L. Goldman D.L. Groves H.E. Rajapakse N.S. Lamb G.S. Tribble A.C. Hersh A.L. Thorell E.A. Denison M.R. Ratner A.J. Newland J.G. Nakamura M.M. Multicenter interim guidance on use of antivirals for children with coronavirus disease 2019/severe acute respiratory syndrome coronavirus 2. J. Pediatric Infect. Dis. Soc. 2021 10 1 34 48 10.1093/jpids/piaa115 32918548
    [Google Scholar]
  49. Gerhart J. Cox D.S. Singh R.S.P. Chan P.L.S. Rao R. Allen R. Shi H. Masters J.C. Damle B. A comprehensive review of the clinical pharmacokinetics, pharmacodynamics, and drug interactions of Nirmatrelvir/Ritonavir. Clin. Pharmacokinet. 2024 63 1 27 42 10.1007/s40262‑023‑01339‑y 38177893
    [Google Scholar]
  50. Muhammed Y. Molecular targets for COVID-19 drug development: Enlightening Nigerians about the pandemic and future treatment. Biosafety Health 2020 2 4 210 216 10.1016/j.bsheal.2020.07.002 32838282
    [Google Scholar]
  51. Horby P. Mafham M. Linsell L. Bell J.L. Staplin N. Emberson J.R. Wiselka M. Ustianowski A. Elmahi E. Prudon B. Whitehouse T. Felton T. Williams J. Faccenda J. Underwood J. Baillie J.K. Chappell L.C. Faust S.N. Jaki T. Jeffery K. Lim W.S. Montgomery A. Rowan K. Tarning J. Watson J.A. White N.J. Juszczak E. Haynes R. Landray M.J. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N. Engl. J. Med. 2020 383 21 2030 2040 10.1056/NEJMoa2022926 33031652
    [Google Scholar]
  52. Cao B. Wang Y. Wen D. Liu W. Wang J. Fan G. Ruan L. Song B. Cai Y. Wei M. Li X. Xia J. Chen N. Xiang J. Yu T. Bai T. Xie X. Zhang L. Li C. Yuan Y. Chen H. Li H. Huang H. Tu S. Gong F. Liu Y. Wei Y. Dong C. Zhou F. Gu X. Xu J. Liu Z. Zhang Y. Li H. Shang L. Wang K. Li K. Zhou X. Dong X. Qu Z. Lu S. Hu X. Ruan S. Luo S. Wu J. Peng L. Cheng F. Pan L. Zou J. Jia C. Wang J. Liu X. Wang S. Wu X. Ge Q. He J. Zhan H. Qiu F. Guo L. Huang C. Jaki T. Hayden F.G. Horby P.W. Zhang D. Wang C. A Trial of Lopinavir–Ritonavir in adults hospitalized with Severe Covid-19. N. Engl. J. Med. 2020 382 19 1787 1799 10.1056/NEJMoa2001282 32187464
    [Google Scholar]
  53. Hill A. Garratt A. Levi J. Falconer J. Ellis L. McCann K. Pilkington V. Qavi A. Wang J. Wentzel H. Retracted: Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. Open Forum Infect. Dis. 2021 8 11 ofab358 10.1093/ofid/ofab358 34410284
    [Google Scholar]
  54. Beigel J.H. Tomashek K.M. Dodd L.E. Mehta A.K. Zingman B.S. Kalil A.C. Hohmann E. Chu H.Y. Luetkemeyer A. Kline S. Lopez de Castilla D. Finberg R.W. Dierberg K. Tapson V. Hsieh L. Patterson T.F. Paredes R. Sweeney D.A. Short W.R. Touloumi G. Lye D.C. Ohmagari N. Oh M. Ruiz-Palacios G.M. Benfield T. Fätkenheuer G. Kortepeter M.G. Atmar R.L. Creech C.B. Lundgren J. Babiker A.G. Pett S. Neaton J.D. Burgess T.H. Bonnett T. Green M. Makowski M. Osinusi A. Nayak S. Lane H.C. Remdesivir for the Treatment of Covid-19 — Final Report. N. Engl. J. Med. 2020 383 19 1813 1826 10.1056/NEJMoa2007764 32445440
    [Google Scholar]
  55. Mangalmurti N. Hunter C.A. Cytokine Storms: Understanding COVID-19. Immunity 2020 53 1 19 25 10.1016/j.immuni.2020.06.017 32610079
    [Google Scholar]
  56. Zhang L. Lin D. Sun X. Curth U. Drosten C. Sauerhering L. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 2020 368 6489 409 412 10.1126/science.abb3405
    [Google Scholar]
  57. Baum A. Ajithdoss D. Copin R. Zhou A. Lanza K. Negron N. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science 2020 370 6520 1110 1115 10.1126/science.abe2402
    [Google Scholar]
  58. Zhou Y. Fu B. Zheng X. Wang D. Zhao C. Qi Y. Sun R. Tian Z. Xu X. Wei H. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl. Sci. Rev. 2020 7 6 998 1002 10.1093/nsr/nwaa041 34676125
    [Google Scholar]
  59. Cheng T. Li Q. Zhou Z. Wang Y. Bryant S.H. Structure-based virtual screening for drug discovery: A problem-centric review. AAPS J. 2012 14 1 133 141 10.1208/s12248‑012‑9322‑0 22281989
    [Google Scholar]
  60. Kitchen D.B. Decornez H. Furr J.R. Bajorath J. Docking and scoring in virtual screening for drug discovery: Methods and applications. Nat. Rev. Drug Discov. 2004 3 11 935 949 10.1038/nrd1549 15520816
    [Google Scholar]
  61. Karplus M. McCammon J.A. Molecular dynamics simulations of biomolecules. Nat. Struct. Biol. 2002 9 9 646 652 10.1038/nsb0902‑646 12198485
    [Google Scholar]
  62. Hughes J.D. Blagg J. Price D.A. Bailey S. DeCrescenzo G.A. Devraj R.V. Ellsworth E. Fobian Y.M. Gibbs M.E. Gilles R.W. Greene N. Huang E. Krieger-Burke T. Loesel J. Wager T. Whiteley L. Zhang Y. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett. 2008 18 17 4872 4875 10.1016/j.bmcl.2008.07.071 18691886
    [Google Scholar]
  63. Hajduk P.J. Greer J. A decade of fragment-based drug design: Strategic advances and lessons learned. Nat. Rev. Drug Discov. 2007 6 3 211 219 10.1038/nrd2220 17290284
    [Google Scholar]
  64. Horby P. Lim WS. Emberson JR. Dexamethasone in Hospitalized Patients with Covid-19. N. Engl. J. Med. 2021 384 8 693 704 10.1056/NEJMoa2021436
    [Google Scholar]
  65. Gottlieb R.L. Nirula A. Chen P. Boscia J. Heller B. Morris J. Huhn G. Cardona J. Mocherla B. Stosor V. Shawa I. Kumar P. Adams A.C. Van Naarden J. Custer K.L. Durante M. Oakley G. Schade A.E. Holzer T.R. Ebert P.J. Higgs R.E. Kallewaard N.L. Sabo J. Patel D.R. Klekotka P. Shen L. Skovronsky D.M. Effect of Bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19. JAMA 2021 325 7 632 644 10.1001/jama.2021.0202 33475701
    [Google Scholar]
  66. von Delft A. Hall M.D. Kwong A.D. Purcell L.A. Saikatendu K.S. Schmitz U. Tallarico J.A. Lee A.A. Accelerating antiviral drug discovery: Lessons from COVID-19. Nat. Rev. Drug Discov. 2023 22 7 585 603 10.1038/s41573‑023‑00692‑8 37173515
    [Google Scholar]
  67. Schoof M. Faust B. Saunders RA. Sangwan S. Rezelj V. Hoppe N. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science 2020 370 6523 1473 1479 10.1126/science.abe3255
    [Google Scholar]
  68. Del Valle D.M. Kim-Schulze S. Huang H.H. Beckmann N.D. Nirenberg S. Wang B. Lavin Y. Swartz T.H. Madduri D. Stock A. Marron T.U. Xie H. Patel M. Tuballes K. Van Oekelen O. Rahman A. Kovatch P. Aberg J.A. Schadt E. Jagannath S. Mazumdar M. Charney A.W. Firpo-Betancourt A. Mendu D.R. Jhang J. Reich D. Sigel K. Cordon-Cardo C. Feldmann M. Parekh S. Merad M. Gnjatic S. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 2020 26 10 1636 1643 10.1038/s41591‑020‑1051‑9 32839624
    [Google Scholar]
  69. Ibrahim M.A.A. Abdelrahman A.H.M. Allemailem K.S. Almatroudi A. Moustafa M.F. Hegazy M.E.F. In Silico evaluation of prospective anti-COVID-19 drug candidates as potential SARS-CoV-2 main protease inhibitors. Protein J. 2021 40 3 296 309 10.1007/s10930‑020‑09945‑6 33387249
    [Google Scholar]
  70. Cheke R.S. The molecular docking study of potential drug candidates showing anti-COVID-19 activity by exploring of therapeutic targets of SARS-CoV-2. Eurasian J. Med. Oncol. 2020 10.14744/ejmo.2020.31503
    [Google Scholar]
  71. Kemisetti D. Amin R. Alam F. Gacem A. Emran T.B. Alsufyani T. Alqahtani M.S. Islam S. Matin M.M. Jameel M. Novel benzothiazole derivatives synthesis and its analysis as diuretic agents. Evid. Based Complement. Alternat. Med. 2023 2023 1 5460563 10.1155/2023/5460563
    [Google Scholar]
  72. Badikela R. Krishna., Rathnakar, Ch., Durgaprasad, Kemisetti., Vijayaraj, Surendran., and Parameshwar R. Synthesis, Molecular docking, Molecular properties estimations and Anti-inflammatory activity of 5,7-dihydroxy-3′ prenyl flavone. Heterocyclic Lett. 2022 12 979 804
    [Google Scholar]
  73. Packialakshmi P. Gobinath P. Vijayakumar K. Ali D. Alarifi S. Ravindran B. PitchaiSangan Surendrakumar R. Synthesis of Isatin Derivatives Using Silver Nanoparticles as Green Catalyst: Study of Molecular Docking Interactions in SARS-CoV-2 3c-Like Protease and Determination of Cytotoxic Activities of the Compounds. J. Nanomater. 2021 2021 1 17 10.1155/2021/7241699
    [Google Scholar]
  74. Faruk A. Durgaprasad K. Kumar Dey B. Quinazoline-purine derivatives as antidiabetics: Synthesis, in- silico and in-vitro evaluation. 2023 13 1 185 203
    [Google Scholar]
  75. Narasimha K. Kumar J. Kumar D B. Synthesis, docking and biological evaluation of N- [4-(1H- Benzimidazole- 2- Yl)- Phenyl]-3-(substituted)-acrylamide derivatives as antimicrobial, anthelmintic and antioxidant agents. Heterocycl Lett 2022 12 653 68
    [Google Scholar]
/content/journals/covid/10.2174/0126667975310159241008050626
Loading
Revisiting the COVID-19 Pandemic: A Comparative Analysis between Traditional and Synthetic Modes of Treatment with the Aid of In-silico Methods
Bentham Science Publishers ; https://doi.org/10.2174/0126667975310159241008050626
/content/journals/covid/10.2174/0126667975310159241008050626
/content/journals/covid/10.2174/0126667975310159241008050626
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: azithromycin ; COVID-19 ; curcumin ; molecular docking ; pandemic ; camphor ; synthetic treatments ; antiviral properties ; in-silico methods
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test